Capital Research Global Investors Gilead Sciences, Inc. Transaction History
Capital Research Global Investors
- $466 Billion
- Q4 2024
A detailed history of Capital Research Global Investors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 57,946,228 shares of GILD stock, worth $6.38 Billion. This represents 1.15% of its overall portfolio holdings.
Number of Shares
57,946,228
Previous 61,799,671
6.24%
Holding current value
$6.38 Billion
Previous $5.18 Billion
3.33%
% of portfolio
1.15%
Previous 1.12%
Shares
30 transactions
Others Institutions Holding GILD
# of Institutions
2,088Shares Held
1.02BCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$13.3 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.7 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.89 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.64 Billion0.23% of portfolio
-
Wellington Management Group LLP Boston, MA35.7MShares$3.92 Billion0.62% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $138B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...